Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1847 results
February 2017
-
Press release
Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow… -
Press release
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt… -
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelle
Les actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free cash-… -
Press release
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients… -
Story Patient Perspectives
Meet T.J. Sharpe
Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
-
In The News
Novartis Access perspectives: Pharma partners with African countries on chronic diseases
In an editorial for Pharmaphorum, Dr. Kiliko, Head Customer Services at Mission for Essential Drugs and Supplies (MEDS), showcases how Pharma companies play a vital role in improving access-to-… -
Press release
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with… -
Press release
Sandoz Pharmaceuticals AG a reçu la certification Top Employer Suisse 2017
Sandoz Pharmaceuticals AG a été officiellement certifiée par le Top Employers Institute pour les conditions de travail exceptionnelles qu'elle offre à ses employés en SuisseL'étude internationale… -
Press release
Sandoz Pharmaceuticals AG als Top-Arbeitgeber Schweiz 2017 ausgezeichnet
Sandoz Pharmaceuticals AG wurde offiziell vom Top Employers Institute für ihr hervorragendes Mitarbeiterangebot in der Schweiz ausgezeichnet Die jährliche internationale Forschungstätigkeit des… -
Featured News
Medical researchers using new tools to turn science fiction into science fact
Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.
January 2017
-
Press release
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC) Approval addresses unmet… -
Story From Our Labs
Countering the genome reprogramming of cancer cells
Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model